Final Results

Summary by AI BETAClose X

Arecor Therapeutics plc reported its full-year results for the 12 months ended December 31, 2025, highlighting progress in its lead product AT278, a concentrated insulin for automated insulin delivery systems, with a co-development deal signed with Sequel Med Tech and positive FDA feedback. The company also advanced its oral peptide delivery platform and secured three new formulation development collaborations, generating over £1 million in pre-license revenue. Financially, Arecor raised $11 million in non-dilutive funding through a royalty financing agreement with Ligand Pharmaceuticals, though total revenue decreased to £3.1 million from £5.1 million due to the cessation of operations at Tetris Pharma. The company ended the year with £6.1 million in cash and cash equivalents, an increase from £3.2 million in the prior year.

Disclaimer*

UK 100

Latest directors dealings